Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Evaluate which blue chip crypto is safest for beginners, focusing on liquidity, track record, and risk-aware starter strategies.
21,622 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Nespresso taps Dua Lipa as its new global ambassador, signaling a deliberate shift from the Clooney era to a Gen Z-fo...
Stellantis faces a tougher profitability and cash-flow comparison with its peers. But for patient investors, the long...
Shay Capital reduced its PureCycle stake in the latest 13F filing, prompting questions about the stock's future. This...
A bold 17-inch Wimbledon hat by a global star sparked more than fashion chatter — it raised real questions about cost...
New York’s upstart candidate Jack Schlossberg argues JFK would be alarmed by America’s global standing, while acknowl...
GE Aerospace delivered strong results in 2026, but the broader XLI index outpaced the stock through July. Here's what...
Three global e-commerce leaders are trading at bargain prices as reinvestment cycles press on near‑term earnings, pot...
A veteran Southern California luxury team is switching brokerages, moving to Sotheby’s International Realty – Monteci...
As hurricane risk and losses climb, lenders are expanding financing options for these round homes resilient designs, ...
A big EBITDA leap can capture attention, but insider trades often tell a different story. This guide explains why thi...
Young graduates facing scarce first jobs as data show the entry-level market worst it’s unfolding despite a steadier ...